New Survey Reveals Growing Problem With AI | Trading the Markets With AI, April 15, 2026

20:32Kris Bullock:seeing too uh my i was just talking to my friend literally like the other day about this because you know the rise of local llms is coming you know into fruition we've seen it in google trends Like people are searching, like how to set their own local LLM. And I was talking to my friend about it. And his reasoning behind not wanting to use AI was because he doesn't want these companies to have his data and his intimate information. I was like, if you don't think they have our conversation right now, you're in for a rude awakening, my friend. Sure.

21:05Bijan Maleki:Yeah, no. I mean, absolutely. But it is nice.

21:10Kris Bullock:I'm sorry. Go ahead, Chris. Sorry.

21:11Bijan Maleki:I was going to say, it is nice that there is the option to have this local inference. And I know we're going to, the technology is evolving further towards that, you know, as we talk about edge compute and things like that constantly. But yeah, hopefully that will overcome some of those concerns. Anyway, sorry, I interrupted you. Yeah.

21:30Kris Bullock:Before we move on to the to the pharmaceutical article, just tie a bow on this one. I'll leave you with the laws of physics. Everything has an equal and opposite equal and opposite reaction. Right. So I think for all the bad and the anxiety stuff that you think of with A.I. on the other end of that, it's equally as good. If people are working to attack and like use quantum hacking on the other end of that, people are using A.I. to defend against that kind of stuff. So, yeah.

22:00Bijan Maleki:Yeah, hopefully the good wins in the end, you know?

22:05Kris Bullock:So what is Big Pharma doing right now?

22:09Bijan Maleki:And should we be worried? Well, I know, right? So Eli Lilly has already kind of gotten into this game some time ago, basically partnering with large AI to essentially help them research and help them, you know, because like all of these clinical trials And all of this research, it analyzes just massive, massive data sets, you know, that take normally takes years and billions of dollars to process through. And that's why drugs cost so much. That's why pharmaceuticals are so expensive. It's not just because they they want to price judge everybody. It's because some of the stuff literally takes billions of dollars to research and develop, you know, and that's where AI is coming in.

22:50Bijan Maleki:And AI is basically helping them process all of this information on a much quicker basis and just hopefully get to the end result faster. And so, yeah, basically what has happened here? So there's two big stories here. One of them is Novo Nordisk. Did I say that right? Novo Nordisk. They announced a strategic partnership with OpenAI to basically integrate its most advanced AI capabilities directly into drug development, just like I was saying, which, you know, again, cuts down research, basically just cuts the time it takes to get to clinical trials so that they can start testing these things.

23:29Bijan Maleki:I think that's an easy, easy, no-brainer use case for AI, because again, this is just so much information. And so this is going to be huge. The next story is in this, what was it? Not Novartis, the other one. Novartis. Novartis. Yeah, Novartis. So Novartis basically joined the Anthropic Board of Directors. They took a seat on the Anthropic Board of Directors. So at the board level now, we've got CEOs joining AI boards and essentially just directing the direction of AI and pharmaceuticals in one sort of cohesive thing. And so, yes, both approaches designed to slash the process, the time it takes to develop new pharmaceuticals.

24:18Bijan Maleki:And I think, again, we're only going to see that continue. I'm sure these aren't going to be the only three companies that do this. It's a no-brainer use case. and um i think it's going to lead to it can only lead to good things you know i've heard lots of other people not myself included but say ai is going to cure cancer you know um and it can do also also researching things like um you know genetics and things like that and you know genetic codes and genetic sequences and and find and create sort of bespoke pharmaceuticals that will attack individual cases, you know, and things like that much, much more cheaply than ever was possible, you know.

24:58Bijan Maleki:And so I'm pretty excited for this, honestly. I think this, you know, this is going to have a huge impact on just longevity in the future. And I can't wait. I think it's massive.

25:10Kris Bullock:With the use of AI, right? I'm looking at it also from maybe an investment angle because I'm thinking of Joe Bland, who recently called out United Healthcare stock. And now I'm thinking of something like Big Pharma and like Novo Nordisk using this, right? That's going to speed up their research time, right? It's going to cut their costs like significantly, right? It's going to allow them maybe to put out better and more medications. What do you think this does for their stock?

25:42Bijan Maleki:Yeah, I mean, it can only improve. It's funny, I actually have a watch list in my trading view of pharmaceutical stocks, you know, and I do keep track of them. And they're still a little bit slow moving, but it can only do good. You know, it can only be a good thing. One thing I want to point out to you for people maybe who are new to AI, what we're seeing here with these companies, don't think of this like, oh, they're just going on chat GPT and like asking, how do I make this drug better? You know, like that's not having it sort of having it sort of hallucinate these ridiculous answers and being like, great, here's a new drug.

26:18Bijan Maleki:You know, like that's not at all what's happening here, like at all. know that these companies, these pharmaceutical companies have access to the most advanced models that are not available to the public, that are very bespoke to what is going on, that are trained specifically on the data, the internal data and the internal sort of, you know, scientific process that these companies are using. So this is not the same thing at all as, as, as like what I just said. So don't think this is going to be, oh, I'm going to get some drug and it's going to, you know, make me whatever grow a second arm because of whatever because of ai you know it's it that's not that's not what's happening here like at all so yeah could you imagine oh my god thank god

27:01Kris Bullock:they're not doing that um on just to play a little devil's advocate though on the other side of that i don't know how i feel about novartis joining uh open ai's board i don't know if i like that because i don't know what type of influence they can have because like you see you hear these stories about like how, you know, pharmaceutical companies are always like, you know, giving news agencies ad revenue and therefore like news isn't really reporting so much on like what these companies are doing. I'm a little concerned what that can mean for the AI too. But, you know, that's just me putting on my tinfoil hat and wondering where it can go.

27:40Bijan Maleki:I mean, sure, sure. I get what you're saying. I guess we'll see. Hopefully that means something good in the end. But yeah.

27:49Kris Bullock:Let's make sure we test open AI and make sure they stay honest on that.

27:55Bijan Maleki:Or it's actually anthropic where they join the board. But yes.

27:58Kris Bullock:Okay. Anthropic.

27:59Bijan Maleki:Yeah. All right.

28:02Kris Bullock:Well, another story that we've got, a very interesting one as well, is what, AI and sports betting? like do we do like what's going on here like are you are you are you like considering this as an

28:21Bijan Maleki:angle like what's going on well based on this article i'm not because it didn't do very well in fact it did it did very poorly in fact all three tests or no i think they tested like eight top models um they were all given kind of a virtual bankroll to bet on a full premier league season and all of them lost money and some of them went fully bankrupt. Some of them lost all the money. And they actually didn't do better than this Kelly bench, this sort of spreadsheet thing that was developed back in the 90s. They all knew what it was and they all understood how it worked, but none of the AI models would actually adjust their code to actually utilize the strategy, which was sort of funny and strange.

29:03Bijan Maleki:I'm sure this could be tweaked and I'm sure that Like you could go through this process and go, okay, well, they all failed. Here's what they did wrong. Let me try it again and make sure they do X, Y, Z differently this time to make up for that. So, I mean, who knows, but based on this, I'm not ready to do it yet. Though I still think there's an angle in terms of like prediction markets and having them find, you know, an angle there as opposed to just straight betting on sports. because a lot of times it's like the AI can understand the process. They can understand the formula, but they don't, they can't necessarily process the real world.

29:38Bijan Maleki:You know, like if an athlete gets injured or if, you know, even just intangible things like, like momentum, you know, with a team and morale and things like that, you know, like they can't, they don't know all of that stuff. That's, that's stuff that an AI can never, never process. And so that's always going to be, I think, a hindrance in this regard in terms of like betting purely on sports, you know, directly. But yeah.

30:03Kris Bullock:The way I'm thinking about this right now is this is coming. It's not here yet. It's obviously has a lot of flaws, but that just means there's an opportunity for people that want to address this type of market. Prediction markets are only growing. Calci, Polymarket, they're like, worth$10 billion each right now. And that's only going to continue billions upon billions of dollars in volume on both of them. Once election season comes, it's going to be really mainstream again. So I just see this as an opportunity. And while the AI, like you said, Chris, because you're spot on, the AI, it has some issues with context and literal, real world current different applications, but that doesn't mean that the AI can't help you solve that problem to automate it.

30:53Kris Bullock:So, you know, got to get a little creative, guys. This is definitely something that I think is going to be coming down the line, especially with the rise of prediction markets. So stay tuned for some of these things.

31:07Bijan Maleki:Yeah, exactly. I think this is maybe just an experiment to go, OK, here we tried this. It didn't work. But now we understand why it didn't work. And it's real easy to try something else and learn from those mistakes. Certainly incorporating prediction markets into sports betting with AI, that seems like a no brainer, because it can leverage the insight it gets from just the prediction markets to make sports bets. The prediction markets know what's going on in the real world because that's what's driving them, because that's driven by humans. And so it's a lot easier for it to take that information and produce accurate sports bets i think based on what the the actual humans are interpreting into

31:49Kris Bullock:the prediction markets you know yeah and sports in particular is like such a hard use case for this because like you have the whole thing with changing lineups injuries like you know last minute substitution weather can play a part in all of this as well absolutely like there's so many variables like that context and that memory can really that that can cause ai to make those mistakes. So that's, I think sports might be a really difficult use case for this to start out, but it'll come. Yeah.

32:19Bijan Maleki:Yeah. I agree. I agree. Yeah.

32:22Kris Bullock:So speaking of the last story before we move on to some, some technical indicators and some charts, if you are a struggling company, Chris and I have just the solution for you. Pivot to AI because, oh my God, everyone has heard about Allbirds right now today. And what a bump they've experienced recently. Although still not to their all time high though, right?

32:53Bijan Maleki:Yeah, no, not even close. But yeah, it basically went full meme coin today. It was up like over eight X at one point, I think, on the day, which is just bonkers. I mean, what's even happening there? It is interesting, though. There's a lot to kind of pick apart here. So they essentially sold all of their intellectual property, their manufacturing. They literally just said, we're selling the shoe business entirely. So they sold their shoe business for$39 million and bought a bunch of AI compute hardware, essentially. And they're going to lease it out and provide, you know, AI compute power, essentially.

33:33Bijan Maleki:But it's interesting because they go from competing in a, you know, pretty competitive shoe market where they already weren't doing well to competing in a very competitive AI compute market, you know. So before where they were competing with, I mean, I don't know, whoever. Now they're competing with the likes of like CoreWeave and, you know, AWS and Microsoft Azure and all these big hyperscalers. Like, is that really a better market? I don't know. You know, like, it's not like those guys have way more money to throw around than the, you know, the little bit of money that these guys cobbled together to kind of kind of do this.

34:07Bijan Maleki:So I don't know. It's it's definitely it's it's tricky. It's funny, though. But yeah, it's definitely funny.

34:17Kris Bullock:I love the memes that have come out of this. But like, I do like, honestly, I know they're a shoe company and like it's like, where's their expertise in this pivot? obviously they're going to hire some people that are experts in this and they're going to have you know some type of you know situation they they have their ducks in a row i would imagine if they're making this type of huge pivot it's going to come out of nowhere what i think about this is and i and i think maybe the way all birds is thinking about this is this is a like obviously infrastructure isn't new right the aws is the azure they've been there already but the pivot to AI and the massive demand for all of these data centers within AI is kind of a new market unto itself.

35:01Kris Bullock:Whereas like the shoe market is already established. That thing is old school. You're not going to even get close to Nike, Adidas and, you know, even Fila's market share for that matter. But whereas this is like a generally new sector, they probably have, I think by them making this pivot, they'll be better positioned in this sector than they were in the shoe sector. That's how I'm viewing this.

35:27Bijan Maleki:Yeah, it is safe to say certainly the pie is bigger. There's more to go around here. And there is massive demand for AI compute everywhere. And so, of course, they will have buyers for their service. But how big a slice of pie they end up with in the end, I don't know. I guess that remains to be seen. Certainly, they are going up against some huge money, you know, people that with billions of dollars of resources. And so, but again, maybe, maybe it's just, maybe the pie is plenty big enough. Um, and, and if you are, if you happen to be a fan of Allbirds shoes, they are still around. They sold all of that intellectual property to another company who will continue to produce Allbirds shoes using the same tooling, the same equipment, the same, it's the same pro hopefully it's the same product.

36:13Bijan Maleki:I mean, I think anyway, same branding, everything. So Allbirds as a shoe company will continue to exist. It'll just be owned by a different corporation on top, basically.

36:25Kris Bullock:Interesting stuff. We'll be following Allbirds now, that's for sure. So, all right, guys, we're going to head over to the Real Vision platform and we are going to check out Chris's new AI indicator, or actually a new technical indicator that he created using AI. And we're going to take a look at some AI charts as well. So come on over, join us on the Real Vision platform. We'll see you guys in a bit.

36:56Kris Bullock:All right, everyone. Welcome back, Real Vision members only. So for those of you that tuned into our live TA show in Discord on Monday, this might be just a review for you, but we definitely wanted to showcase this really cool indicator that Chris built using AI. So Chris, I'm going to shut up now. Take it away, my friend.

37:24Bijan Maleki:Yeah, so I figured, like I said, I kind of went through a good bit on Monday, but I wanted to revisit it this time through the lens of how it came to be, why I created it, the process I used to create it. things like that. So this one was a little bit different for me in that I didn't even necessarily know that I needed it right away. Like I was having this long conversation with Claude. It started out about, I was using the megatrend indicator and I was trying to figure out what parameters it needed or what levels it needed to actually flip green. And so I was going back and forth and, you know, like an hour into this long conversation that I was having with Claude, just breaking down the probabilities of, you know, how the next sort of month or so is going to play out with charts, it became apparent that I needed an indicator that showed real yields.

38:16Bijan Maleki:And so like, you know, I'm not going to scroll all the way through this, but eventually I'm like, oh, okay, I need this. And so here I am. Can you make a trading indicator that shows both the long and short end? I meant to say real yields here. Thankfully, it knew what I meant. And so, yeah, it's like of course here you go here i made this line you know i'll make three different threshold areas and boom spit it out done and i love to i love using claude for trading view indicators in particular because it's so easy compared to making dashboards and everything it literally just spits out a script you just copy and paste it open the pine editor in uh in trading view paste it in there load it on the chart um nine times out of ten it works immediately right out of the gate Occasionally you get a one minor syntax error that it has to fix.

39:06Bijan Maleki:So yeah, it threw it up. And let me pull it up here. So basically it made this, which again, if you watch the show, you saw. And at first it was only showing me the forward-looking real rates, because that's kind of what I was, that's the angle I was coming at from the conversation that I was having. And so as I was looking at this, I was like, this is helpful. and it I mean it did this histogram automatically all on its own it you know it kind of had the the two-year ten-year crossover all on its own so it sort of inferred a lot of things that I wouldn't have even thought about which is what I love about Claude it always sort of knows what you want and then some and it gives you more than you actually ever asked for and and it's almost always better it knew to make like the ten-year one in particular the most important and so it made it a big bold line whereas the rest of them are thinner lines also it adjust is like adjust the opacity of the lines based on where they are in the shading area.

40:05Bijan Maleki:And so I thought that was kind of cool too. But then I got to looking at it and I was like, well, this is cool. But one, since it's only using forward looking, it only goes back to like 2008. And I want older historical data. And then two, I also wanted kind of the real time, the sort of realized real yields in addition to the implied base real yields. And so I told it to do that. And it kicked me out a new version through a little checkbox up here. And so in the in the settings, so now I can click this checkbox, and it pivots from forward looking to immediate sort of realized real yields. Same everything else, which was like, yeah, this is this is perfect.

40:44Bijan Maleki:This is exactly what I need. So and I kind of tweaked a little bit here and there and had it adjust the shading. And And, but yeah, it was, it was literally that simple. I spent almost no time on this, you know, probably 10 or 15 minutes total, you know, like, and this is such a usable indicator and I can throw it up on any chart. Oh, and then what I like to do now is I love, I'm like, this is cool. And this is super useful. So I, of course I want to share it with the trading view community and the real vision community and, and with trading that you can publish any idea or any indicator. and prior to using AI to publish stuff and create stuff, it was always such a slog to like, you go into the publishing sequence on TradingView to make it public and you have to write out this description and kind of tell it what it is.

41:33Bijan Maleki:And so of course I just say, Claude, write me out the description, write me out the instructions, explain what this indicator is, explain how it works, explain the instructions. And of course it just kicks you out of full, really in-depth, like amazing, well, here, I'll just pull it up, in-depth explanation of what this is and how it works. And so, you know, it gave this great table and great instruction set. And, you know, even explaining sort of why real yields are relevant and why would you even want to use this indicator in the first place? Like it has all of that in there and it makes it super easy and you know then I can share it with everybody else and easy peasy so um yeah I just it I think it's so cool to be able to have this at our disposal to be able to create indicators on on a whim I mean literally on a whim you're just having a conversation and next thing you know you have this indicator that brings you all this new amazing insight no time at all and and you're everything's you know you're better off for it and you can share it with everybody so it's just a win-win across the board.

42:38Kris Bullock:And did you say, I'm sorry, did you say it took you like 10 minutes to make that?

42:43Bijan Maleki:I mean, yeah, literally. Well, I mean, the first iteration, probably it took Claude not even a minute. I mean, it's so, because they're not that complicated. Like really, like here's the code. Let me just pull up the Pine Editor. You know, whatever. It's 113 lines of code it took to do this. And so it was nothing. It was literally nothing. It just, here you go. Here's your script. Copy, paste, boom, done. Yeah. And it knew exactly what it needed. It pulled everything up. And yeah, there were no issues whatsoever. And so you can tell it to change colors. You can tell it to change line weights and things like that.

43:28Bijan Maleki:And so, yeah, it's just so easy. And I think it's one of the, I don't know if it's underutilized, it's one of the cooler things that I use Claude for, because again, it's so simple. And it helps you just get more insight because there are limitations in terms of like, if you go into the community indicators and look for stuff, it's not always there. It's hard to find stuff or maybe somebody hasn't made something that you're looking for. And so to have the immediate ability to create something out of thin air that gives you additional insight that can help you be a better investor, better analyst going forward.

44:04Bijan Maleki:Yeah, again, it's just this is the this is the amazing world we live in right now. And I love it so much. It's just it's amazing.

44:13Kris Bullock:It really is, honestly. I don't know what those people in the Stanford article are worried about when you have stuff like this that you can use, right? just incredible. Yeah.

44:25Bijan Maleki:And this is probably, I don't know that like I've probably made six or eight really cool indicators, you know, with, with using the same thing. And a lot of times, like I said, it's either I'm having an existing conversation and something comes up where I didn't even know I needed this or other times it's like, I know I kind of need something, but I don't really know what I want it to look like. And so I'll just start again, having a conversation with Claude. Hey, I kind of need this information. Can you help me figure out a way to extract this and present it and display it. And it always does a better job at creating something than what I can come up with in my own head, you know?

44:59Bijan Maleki:And so, yeah, it's just fun. It's fun to, I find myself constantly sitting here thinking like, well, what else can I make an indicator for? Or what other information can I glean from something, you know? And so I think if you're getting into charts and, you know, you're looking at this, like I encourage you to go on Claude or whatever your favorite vibe coding LLM is and just start having to crank out random indicators for you. It's almost like even if there is an indicator that exists, have it make you one anyway, you know, just to a lot of times, like there's been even instances where I found one and like, it was cool, but I posted it on Claude.

45:40Bijan Maleki:I was like, can you kind of make this better? Can you improve on this in any way? And it'll, it'll do that too, you know? um and so yeah it's uh it's it's been it's it's like a really valuable addition to just trading view on its own you know it kind of expands the the capabilities of it far beyond what you get just right out of the box you know and so um yeah get out there and make indicators people like it's it's super fun it's super cool and even if like you don't want to make it like

46:09Kris Bullock:you just said chris you don't want to make it brand new i'm sure there are i mean not sure there definitely are so many indicators out there. And I'm sure there are some that you guys are using where that you love these indicators, but you wish it had like just a little something extra to it. Have Claude, add that extra. And now you have your own custom indicator, right? And you don't have to build one from scratch. Just take what you already know, love and use and add a spin to it. And now you've got a super indicator. And another, I want to take it even a step further, because Chris mentioned how he liked to share this with the TradingView community and share with the community in general, create these indicators and share them within Real Vision.

46:48Kris Bullock:People like Chris and Berger and a bunch of our other people that are using TradingView and creating their own indicators will very likely check out the one that you made, maybe test it out and give you some feedback as well. And you guys can tinker with it also because I literally just posted in the Pro Chat and Discord this morning, a 24-hour summary of that chat, right? And then Berger responds to it with a cool prompt that I can add and how I can really make it cool and add links and add a leaderboard and all that. So that's the hive mind right there, guys. And I'm going to go do that. And I'm going to coordinate with Berger.

47:26Kris Bullock:And now we're going to make a super cool summary bot in Discord for all of you guys. It's going to be awesome. So anyway, that wasn't part of it. I just got really excited and had to mention that. uh chris should we uh should we maybe end up here maybe taking a look at some some charts and seeing

47:44Bijan Maleki:what what the markets do yeah well yeah definitely i wanted to start with the bird the all verbs chart because i i had to share that it's just bonkers looking at it it's so funny i mean it was literally it's at one point it was up 850 today and so it opened at two dollars it's at 17 it got as high as 25 man i'm like man can you imagine knowing about this like uh you know of course someone definitely somebody did somewhere i i'm sure uh but the funny thing is the funny thing is you got to zoom out because if you look at the zoomed out suddenly the it's it's not nearly as good of a picture overall like you're like oh okay now i get why they pivoted you know I mean, what did it IPO at?

48:32Bijan Maleki:Like five, I can't even see it up here. Five, like 650, something like that. So it's back up to$17 people. So no. Also, don't go chasing this. This is like not, if you weren't already in, you missed the boat, like for sure. this is a sell the news thing absolutely it's already down you know uh 200 percentage points from from where it peaked so yeah it's already it's already on its way this isn't the kind of thing that's going to keep ripping um or at least not after giving back most of this first but if their data center business proves to be profitable i mean sure that could drive the price up which is it's worth like keeping a keeping on your radar you know because again that we talked about that That pie is big.

49:20Bijan Maleki:Maybe that may, you know, and this stock is somewhat adjusting to the new revenue potential of the stock. I mean, that's partially what's driving this beyond just the hype of it. So yeah, I mean, if suddenly their earnings are killing it and they're actually making money, then this will go up. But you don't want to buy a big hype candle like this. I mean, that's just asking for trouble. Like that's, that's number one rule of thumb, you know? both. But yeah, outside of that, it's funny, stocks generally are down overall on the day, but there's so much that's doing well. And I keep, I have this, this AI watch list that I continue to add to, you know, every week or two, and it's only getting bigger and bigger.

50:02Bijan Maleki:And there's only, there's more and more IT infrastructure companies that are coming along. There's more and more semiconductor companies that are coming along that are entering, not entering the space so much, but sort of coming into my radar, you know, because there's a lot of companies out there. But I mean, it's funny. I could go through a bunch of these, which I'll just click on some. Memory is continuing to be the number one play. Like it's the scarcity play. And so we're seeing all of the memory companies, like high bandwidth memory and high performance storage companies, things like Micron, things like Western Digital, things like seagate um things like sandisk let me look at these charts they're they're all like they're all just they're all kind of insane you know and they're it's like this is this is the alt season that i keep talking about that everyone when alt season when all all season is right here and it's in memory people it's in it's in storage companies um yeah they're all just continuing to but there's like new ones that are coming along and and some of the peripheral ones that i've talked about, like Corning continues to rip because they're making fiber optic connectivity for data centers and for edge compute.

51:13Bijan Maleki:That's just, you know, everybody thought, oh, maybe it's cooked here. It came all the way back to its 10-week moving average. Yep, nope, new all-time high is like a week later, basically. Same thing with like Selenese is another one. Now, this isn't straight up into the right like this, but this is because people are like, oh, suddenly, well, now chemicals are more expensive because oil is more expensive, and this company is making all kinds of products, specialty plastics and things like that, that are going to go into IT infrastructure and containers and edge compute devices and robotics and things like that.

51:44Bijan Maleki:And so suddenly there's a huge bid for specialty chemical companies. And we're seeing things like that. So that's another area to look at. Outside of that, I mean, yeah, just all of the semis. Intel, I think, is one that's been killing it lately too. Yeah, like a massive week last week, up 23 % last week. What was another one that killed it that I just, oh, Energy too. That's what it was. Bloom Energy up huge last week and this week. So last week it was up 22%. This week it's up 32%. I think off the back of a.

52:20Kris Bullock:Really quickly, just look at this chart though. Like it's like God candle after God candle after. It's just insane.

52:30Bijan Maleki:Right, right. This was a deal. Well, forgive me if maybe it's in here in the news. They signed a deal with a data center company to provide in-house power. Maybe it was Oracle. Yeah, Oracle. Like Oracle, they signed a deal with Oracle to help power Oracle data centers. Because nobody wants to pay the power prices for data centers to be powered. So the data centers themselves are having to provide their own power. So they're signing on with companies like Bloom Energy to create power generation to power their data centers. And so this is, we're looking at backlogged order books here, basically, for power for data center build outs.

53:16Bijan Maleki:And so that's why, yes. And so it's funny when we think of the idea of AI stocks, nobody thinks of Bloom Energy or like Caterpillar, you know, for example. But these are all the companies that are on the periphery that are part of powering this whole revolution. You know, whether it's actually creating the power generators themselves, the gas turbines or the construction equipment needed to build the data centers, you know, or whatever, or the electronics switching gear that are needed to power the data centers and cool the data centers, you know, the HVAC systems, the stuff like that, you know, that not on anybody's radar.

53:55Bijan Maleki:Or what does that have to do with AI? What does Comfort Systems USA that provides duct work have to do with the AI build out? Well, a lot, actually. And just look at their stock. Those data centers generate a lot of heat, and they need to cool them somehow. And so that's where Comfort Systems USA comes in. So you've got to think way outside the box. It's not just the Mag7. It's not just Google and Neta and Amazon and NVIDIA. I mean, sure, those are good, too, but there's so much more to it. I mean, and it's massive and it covers so many different sectors. And all of this speaks to scarcity. You know, all of this is stuff that is in high demand, that there's not enough of, that there's going to be demand for for years into the future.

54:41Bijan Maleki:And it's pretty easy when you think about it through that filter that, you know, that it's kind of a no brainer. Like, oh, well, is there enough of this? No, it's scarce. Yes. Does it need? Is it part of the AI infrastructure? Yes. Okay. It's probably going to do well. Yeah.

54:58Kris Bullock:Chris, do you know if there's like a picks and shovels ETF, like basically ETFs are funds that we can invest in that? Because there's so many, right? Between like, you know, cooling and infrastructure, data centers, semiconductors. It's like, I can imagine some people might, like their brains might get fried trying to figure out like which one to pick, but like it would be a lot more attractive to be able to invest in a fund that has a basket of all of these. Do those exist yet?

55:29Bijan Maleki:To some extent, I don't know one that's super dialed in to this. There are ones that focus on various sectors. There's certainly energy ETFs. There's certainly, even within, like this one is actually just a solar ETF on its own, but there are energy ones, there are power related ones. There's a brand new one that actually just came out a week or two ago, DRAM, that is a memory ETF and it's brand new. Let me kind of go, here, I'll just put this on like the one hour.

56:02Kris Bullock:We just saw those memory stock charts.

56:04Bijan Maleki:Yeah, and not surprising. I mean, it only came out on the second, so it's right at about two weeks old, but, you know, huge gap up from the first day to the second day, huge gap up from the second day to third day. And then, you know, it's just kind of gap after gap. And yeah, and it's only going higher because the memory stocks are only going higher. And I don't have it in front of me. I wish I had a screenshot, but it's primarily composed of three big ones. I want to say Micron is one of them. I'm pretty sure SanDisk is one of them. And then HK Hynix, which is a Korean memory company, and maybe Samsung also is in the mix.

56:45Bijan Maleki:And so those are kind of the big core ones. And then there's a few smaller ones, smaller positions too. So this is a good way to get memory exposure if you don't want to just buy one of those companies. Though it's funny, I've primarily, like I've personally bought Micron off and on throughout out this. And when you look, they all kind of go up and down generally about the same. So it's like, I don't want to just buy one because what if I miss, but they're all sort of doing the same thing. So yeah, you can buy the ETF, but it's like if you just buy one of them or two of them, you'll end up with more or less the same results anyway in the end, it seems like, because they're all hammering it in terms of their revenues and their earnings reports and their projections and all of that stuff.

57:30Bijan Maleki:But yeah, DRAM. Check out DRAM if you want memory exposure. You can access it on any brokerage. Also, you can get it on Kraken if you want to stay within the crypto ecosystem. It's not on Coinbase yet, even though Coinbase is now offering stocks too, but I checked yesterday and it wasn't there, but it is on Kraken. So yeah, that's what I know about that, but there, yes, there needs to be a proper ETF that kind of encompasses a lot of, the problem is, is it's, I mean, this list is 50 or 60 odd symbols. And it's like, at some point it goes from being an ETF to kind of turning into a mutual fund or an index fund, you know, it's like, so you, you, you kind of have to be a little more choosy there, but yeah.

58:16Kris Bullock:Well, let's get a semiconductor ETF out there too. Cause I'd be interested in that if somebody's watching uh chris thanks again for breaking us down through it all and for uh for highlighting that that cool indicator that you created as well um guys we'll be back on monday for live ta and discord and of course we'll be back next wednesday for another edition of trading the markets if you are someone that's working with ai and you want to showcase that give us a give us some shoot us a message and, you know, come on the show. We'd love to have you on until then guys, don't fuck this up and we'll see you all next week.

58:57Kris Bullock:You obviously enjoyed the episode because you're here with me at the end, but listen, don't forget to go to realvision.com forward slash join and grab a free membership. It's an incredible community packed with alpha, great investment ideas and the research that you need to help you unfuck your future. So get started now,

59:16Bijan Maleki:go to realvision.com forward slash join. Ever wanted to explore the world of online trading, but haven't dared try? The futures market is more active now than ever, and Plus 500 Futures is the perfect place to start. Plus 500 gives you access to a wide range of instruments, S &P 500, NASDAQ, Bitcoin, gas, and much more. Explore equity indices, energy, metals, forex, crypto, and beyond. With a simple and intuitive platform, you can trade from anywhere, right from your phone. Deposit with a minimum of$100 and experience the fast, accessible futures trading you've been waiting for. See a trading opportunity?

59:56Bijan Maleki:You'll be able to trade in just two clicks once your account is open. Not sure if you're ready? Not a problem. Plus500 gives you an unlimited, risk-free demo account with charts and analytic tools for you to practice on. With over 20 years of experience, Plus500 is your gateway to the markets. Visit us at plus500.com to learn more. Trading in futures involves the risk of loss and is not suitable for everyone. Not all applicants will qualify. Plus 500. It's trading with a plus.